23.10.2014 Vita 34 AG  DE000A0BL849

DGAP-Adhoc: Vita 34 AG: Positive Development of Business in the First Nine Months of 2014


 
Vita 34 AG / Key word(s): 9-month figures 23.10.2014 07:33 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Vita 34 AG: Positive Development of Business in the First Nine Months of 2014 Leipzig, 23 October 2014 - Vita 34 AG (WKN A0BL84), the largest private stem cell bank in the German-speaking countries, published its financial figures for the first nine months of fiscal year 2014 today. In accordance herewith revenues increased as compared with the prior year's period by 1.7 percent from EUR 9.9 million to EUR 10.1 million. The total operating income in the reporting period rose by 2.4 percent to EUR 10.8 million (prior year: EUR 10.6 million). Thanks to increased revenues and optimization measures implemented in marketing and sales, the earnings before interest, taxes, depreciation and amortization (EBITDA) rose to EUR 1.6 million in the first nine months and were, therefore, 7.2 percent over the value of the prior year's period, which was EUR 1.5 million. EBIT increased by 25.8 percent to EUR 0.8 million (prior year: EUR 0.7 million). The period result of EUR 0.4 million was 52.5 percent higher than the prior year's value of EUR 0.3 million. Thus, the earnings per share improved to EUR 0.16 (prior year: EUR 0.11). On account of the delayed issuance during the year of official approvals for the collection of umbilical cord tissue, the Management Board estimates the operating profit (EBITDA) for the entire year 2014 will be below previous expectations, however, that it will be higher than the prior year's level. With the further issuance of official permits for the collection and storage of umbilical cord tissue, an increasing positive trend with regard to the development of revenues and profits is to be expected for 2015. Additional information: ISIN: DE000A0BL849 WKN: A0BL84 Ticker symbol: V3V Market segment: Regulated Market (Prime Standard) of the Frankfurt Stock Exchange Vita 34 AG Deutscher Platz 5 04103 Leipzig Germany END OF THE AD-HOC NOTICE 23.10.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Vita 34 AG Deutscher Platz 5a 04103 Leipzig Germany Phone: +49(0341)48792-40 Fax: +49(0341)48792-39 E-mail: [email protected] Internet: www.vita34.de ISIN: DE000A0BL849 WKN: A0BL84 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 19,19 20,41 19,93 20,07 28,42 68,94 76,80
EBITDA1,2 1,85 4,72 5,43 5,34 0,81 -3,56 4,00
EBITDA-Marge3 9,64 23,13 27,25 26,61 2,85 -5,16
EBIT1,4 0,14 2,63 2,45 2,38 -3,07 -27,28 -4,65
EBIT-Marge5 0,73 12,89 12,29 11,86 -10,80 -39,57 -6,06
Jahresüberschuss1 -0,33 0,83 0,72 1,50 -3,93 -27,38 -5,20
Netto-Marge6 -1,72 4,07 3,61 7,47 -13,83 -39,72 -6,77
Cashflow1,7 1,53 4,60 6,32 3,98 2,73 -4,49 0,00
Ergebnis je Aktie8 -0,09 0,20 0,18 0,37 -0,63 -1,71 -0,29
Dividende8 0,16 0,16 0,00 0,00 0,00 0,00 0,16
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Vita 34
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0BL84 4,980 Halten 87,85
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
19,15 25,96 0,70 -71,14
KBV KCV KUV EV/EBITDA
8,07 - 1,14 22,22
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 28.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
31.05.2024 30.08.2024 22.11.2024 30.04.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,30% 2,15% -4,96% -15,59%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Vita 34 AG  ISIN: DE000A0BL849 können Sie bei EQS abrufen


Biotechnologie , A0BL84 , V3V , XETR:V3V